 Home > Active Ingredient News > Antitumor Therapy > Express treatment of HER2-positive breast cancer, blockbuster ADC has made positive progress

Express treatment of HER2-positive breast cancer, blockbuster ADC has made positive progress

 Last Update: 2022-08-19
 Source: Internet
 Author: User

▎Edited by WuXi AppTec Content Team

AstraZeneca and Daiichi Sankyo announced today that their Antibody Drug Conjugate (ADC) Enhertu (trastuzumab deruxtecan) has entered the DESTINY-Breast02 Phase 3 trial in patients with unresectable or metastatic breast cance.

Breast cancer is one of the most common forms of cance.

[1] ENHERTU® Significantly Delayed Disease Progression in DESTINYBreast02 Phase 3 Trial Versus Physician's Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cance.

Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progres.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.